---

DISCLAIMER

This information is provided for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Clinicians must apply individual clinical judgment based on the patient's specific presentation and available evidence. Dosages and guidelines may change; always consult current institutional protocols and professional guidelines.

---

Fontana Procedure

Overview

Definition

The Fontana procedure (more commonly and accurately referred to as the Fontan procedure or Fontan pathway) is a palliative single-ventricle repair surgery that aims to separate the systemic and pulmonary circulations in patients born with complex congenital heart defects that preclude biventricular repair (e.g., Hypoplastic Left Heart Syndrome [HLHS], tricuspid atresia, double-inlet left ventricle).

It is the final stage of a staged surgical approach, achieving total cavopulmonary connection (TCPC), where systemic venous blood (superior and inferior vena cava) is directly channeled to the pulmonary arteries, bypassing the functional single ventricle entirely, which then only pumps oxygenated blood to the body (systemic circulation).

Epidemiology

• Incidence: The congenital heart defects requiring the Fontan pathway (Single Ventricle Physiology, SVP) occur in approximately 1/2,000 to 1/10,000 live births. HLHS is the most common etiology.
• Demographics: Patients typically undergo the Fontan procedure between 2 and 5 years of age, following the initial palliation (Norwood) and the intermediate palliation (Glenn or Hemi-Fontan).

Classification

The initial procedure described by Fontan in 1971 has evolved significantly:

1. Classic Atriopulmonary Connection (APC): Direct anastomosis of the right atrium to the pulmonary artery. Largely abandoned due to high incidence of atrial dilation, arrhythmias, and stasis.
2. Total Cavopulmonary Connection (TCPC): The current standard, where systemic venous return is directed to the pulmonary arteries without traversing a ventricle or the atrium.
   • Extracardiac Conduit (ECC): A synthetic graft (e.g., ePTFE) is used to connect the inferior vena cava (IVC) to the underside of the pulmonary artery. This is the preferred technique.
   • Lateral Tunnel (LT): An intra-atrial baffle is constructed to redirect IVC flow through the right atrium to the superior vena cava line, connecting to the pulmonary artery.

Pathophysiology

Mechanism (Single Ventricle Physiology and TCPC)

The Fontan circulation is a passive, passive-driven circulation: 1. Systemic Venous Return: Deoxygenated blood from the SVC (via the Glenn/Hemi-Fontan) and the IVC flows directly into the pulmonary arteries. 2. Driving Force: The flow depends entirely on the superior venous pressure gradient (SVC/IVC pressure minus PA pressure) and relatively low pulmonary vascular resistance (PVR). The systemic ventricle does not provide pulsatile pressure to the lungs. 3. Single Ventricle Function: The sole functional ventricle pumps fully oxygenated blood returning from the lungs into the systemic circulation (aorta). 4. Consequences: The system operates under chronically elevated systemic venous pressure (typically $12-18 \text{ mmHg}$) to overcome PVR, leading to venous congestion (e.g., liver, intestines, lower extremities) and reduced cardiac reserve.

Risk Factors (for adverse outcomes post-Fontan)

• Elevated pulmonary vascular resistance (PVR $> 2-4 \text{ Woods units}\cdot \text{m}^2$; criterion for poor outcome).
• High end-diastolic pressure in the single ventricle (ventricular dysfunction).
• Significant $\text{AV}$ valve regurgitation (Grade $\ge 2$).
• Small or poorly compliant main pulmonary artery.
• Age $> 6$ years at the time of Fontan completion.
• Prolonged or difficult early postoperative course (e.g., chylothorax, prolonged effusion).

Protective Factors (for good Fontan outcome)

• Low PVR ($< 1.5 \text{ Woods units}\cdot \text{m}^2$).
• Normal ventricular function and compliance.
• Competent atrioventricular $(\text{AV})$ valve.
• The presence of a fenestration (initially aids acute stability).
• Optimal nutritional status and early achievement of rehabilitation goals.

Clinical Presentation (Late Complications of Fontan Circulation)

Signs and Symptoms

Presentation Category	Findings
Cardinal Features	Exercise intolerance, dyspnea on exertion, fatigue, cyanosis (mild to moderate), palpitations (from arrhythmias).
Early Signs	Minor edema (ankles), subtle ascites, reduced effort tolerance compared to peers, early morning nausea/vomiting.
Advanced Signs	Severe or generalized anasarca, refractory ascites, Cachexia, protein-losing enteropathy (PLE)-related diarrhea and edema, severe cyanosis, overt heart failure symptoms (e.g., resting dyspnea).
Atypical Presentations	Stroke or transient ischemic attack (paradoxical emboli via fenestration or collateral vessels), nephrotic syndrome (PLE), hepatic dysfunction/cirrhosis (Fontan-associated liver disease, FALDi).

Physical Examination

Component	Findings
Inspection	Clubbing, peripheral edema, abdominal distension (ascites), jaundice (late FALDi), visible signs of poor growth or cachexia.
Palpation	Hepatomegaly (smooth, firm liver), peripheral pulses (may be diminished if low cardiac output), evidence of ventricular heave or displacement.
Auscultation	Murmur of $\text{AV}$ valve regurgitation, possible gallop rhythm ($\text{S}_3$ or $\text{S}_4$ suggesting ventricular failure), muffled heart sounds (pericardial effusion).
Special Tests	Abdominal Girth Measurement (monitoring ascites), Jugular Venous Pressure (JVP) (often elevated, though difficult to measure accurately due to baseline congestion).

Diagnostic Approach (Assessment of Fontan Failure)

History Taking

Key Questions	Red Flags (Urgent Evaluation)
Functional status (METs, exercise capacity, change from baseline)?	Sudden decrease in exercise tolerance or onset of resting dyspnea.
Detailed listing of edema, ascites, weight gain? (Crucial for fluid status)	New-onset or dramatically worsening $\text{AV}$ valve regurgitation symptoms.
Any diarrhea/malabsorption symptoms (suspect PLE)?	Evidence of paradoxical embolism (TIA/Stroke).
Palpitations, dizziness, or syncope (arrhythmias)?	Signs of sepsis, massive pericardial/pleural effusion, or acute liver failure.
Chronic pain (e.g., musculoskeletal, abdominal) or headaches?	Severe systemic hypoxia or hypoxemia despite optimized status.

Laboratory Tests

• First-Line: Complete blood count (CBC - monitor for polycythemia/anemia), Basic Metabolic Panel ($\text{BMP}$ - monitor electrolyte/renal function), Liver Function Tests ($\text{LFT}$s and $\text{INR}$ - crucial for FALDi and coagulation status), Thyroid function.
• Confirmatory (for specific complications):
  • PLE: Serum albumin/protein (low), stool $\alpha_1$-antitrypsin clearance (elevated $> 2.8 \text{ gm/24h}$ suggests active PLE).
  • Arrhythmias: $\text{NT}$-pro$\text{BNP}$ (elevated suggests ventricular strain).
  • Renal: Serum creatinine, urine protein/creatinine ratio (r/o nephropathy).
• Monitoring (Routine Post-Fontan): $\text{INR}$ (if anticoagulated), $\text{NT}$-pro$\text{BNP}$ (trending is key), Ferritin (iron storage).

Imaging

• Recommended (Standard):
  • Echocardiography: Assess single ventricle function (ejection fraction), $\text{AV}$ valve regurgitation severity, Fontan conduit flow (presence/absence of thrombus, size of fenestration), and evidence of effusion.
  • Chest Radiography: Evaluate cardiomegaly, signs of pulmonary venous congestion, and pleural effusions (often bilateral or right-sided).
• Advanced (Specialized):
  • Cardiovascular Magnetic Resonance (CMR) Imaging: Gold standard for quantifying ventricular volumes, $\text{EF}$, and mass; superior visualization of Fontan conduit and patency; assessment of myocardial fibrosis ($\text{LGE}$). Recommended annually or biennially.
  • Cardiac Catheterization (Diagnostic): Essential for accurate measurement of PVR, Fontan pressure (mean $P_{\text{PA}}$), ventricular end-diastolic pressure ($\text{VEDP}$), and assessment of collateral vessels. Often undertaken prior to major therapeutic decisions (e.g., assessing suitability for heart transplantation).
  • CT Angiography: Used to map venovenous collateral vessels (often arising from the azygos/hemiazygos system) that can cause desaturation.

Management (Addressing Fontan-Associated Failures)

Acute Management (Managing Decompensation)

• Immediate: Ensure oxygenation (though high $\text{FiO}_2$ may not help if cardiac output is fixed), administer diuretics (e.g., IV Furosemide $0.5 - 1.0 \text{ mg/kg}$).
• Stabilization:
  • Fluid Status: Strict $\text{I}$/$\text{O}$ monitoring; judicious titration of intravenous loop diuretics. Management can be complex—over-diuresis reduces preload and cardiac output; under-diuresis causes congestion.
  • Arrhythmias: Immediate cardioversion if hemodynamically unstable. Chronic atrial arrhythmias (intra-atrial reentrant tachycardia, $\text{IART}$) are common; manage with antiarrhythmics (e.g., Amiodarone, Sotalol) or radiofrequency ablation.
  • Inotropes: May be necessary if ventricular dysfunction is acute (e.g., Milrinone $0.25 - 0.75 \text{ mcg/kg/min}$).
• Emergency: Mechanical circulatory support (ventricular assist device - $\text{VAD}$) or extracorporeal membrane oxygenation ($\text{ECMO}$) for fulminant single-ventricle failure, typically as a bridge to transplantation.

Chronic Management (Life-long Surveillance)

Intervention Category	Specific Measures
Pharmacological	Anticoagulation: Routinely recommended indefinitely (e.g., Warfarin $\text{INR target } 2.0-3.0$). Aspirin $81 \text{ mg}$ may be used if high bleeding risk, but Warfarin is often preferred, particularly with conduit/lateral tunnel designs.
	Diuretics: Spironolactone and/or loop diuretics for chronic volume management; monitor electrolytes.
	ACE Inhibitors/ARBs and Beta-Blockers: Increasingly used to optimize ventricular loading and neurohormonal status, especially if systemic ventricle dysfunction is present.
	Pulmonary Vasodilators: Use Sildenafil $20-40 \text{ mg}$ $\text{tid}$ or Bosentan if elevated PVR is suspected or confirmed via catheterization, or to address hypoxia.
Non-pharmacological	Exercise: Regular, moderate aerobic exercise is crucial to optimize cardiac output and PVR; limits imposed by SpO2 $< 85\%$ or symptoms.
	Diet: Low-sodium diet for fluid retention; high-protein, medium-chain triglyceride ($\text{MCT}$)-rich diet for PLE.
	Immunizations/Prophylaxis: Standard vaccination schedule; bacterial endocarditis prophylaxis is life-long (Amoxicillin $50 \text{ mg/kg}$ $\text{PO}$ $1 \text{hr}$ prior to high-risk procedures).
Monitoring	Annual cardiac surveillance (Echo, CMR, labs); Liver surveillance (ultrasound, LFTs, $\alpha$-fetoprotein/serum protein electrophoresis every $6-12$ months due to risk of hepatocellular carcinoma); Neurodevelopmental/Psychosocial screening.

Treatment Algorithms

• First-Line (Stable Patient): Optimal medical management ($\text{ACEi}/$\text{ARB}$ + $\text{Diuretics}$ + $\text{Anticoagulation}$ or $\text{Aspirin}$).
• Second-Line (Mild Fontan Failure/Dysfunction):
  1. Catheterization to reassess hemodynamics (Pressures, PVR, $\text{VEDP}$).
  2. $\text{AV}$ valve repair/replacement (if significant regurgitation).
  3. Ablation for $\text{IART}/$\text{Atrial Fibrillation}$.
  4. Selective collateral coil embolization (if desaturation related to collaterals).
• Refractory Cases (End-Stage Fontan Failure):
  1. Fenestration Creation/Reopening: Small interatrial communication (usually $4-8 \text{ mm}$ stent or balloon) to allow right-to-left shunt, decompressing the systemic venous system at the cost of mild desaturation.
  2. Surgical/Transcatheter Revision: Unilateral closure of $\text{PA}$ supplies to reduce flow mismatch, or revision of conduit stenosis/obstruction.
  3. Transplantation: Orthotopic heart transplantation ($\text{OHT}$) is the definitive solution for end-stage Fontan failure.

Complications

Category	Specific Complications	Clinical Significance
Common	Arrhythmias (IART/Atrial Fibrillation)	Affect up to 30\% of patients; major cause of sudden death and functional decline.
	Pleural/Pericardial Effusions	Often chronic or recurrent, requiring tube drainage or pleurodesis.
	Thromboembolism	High risk (5-15\% lifetime risk), often leading to pulmonary emboli or systemic strokes. Mandates strict anticoagulation.
Serious	Protein-Losing Enteropathy (PLE)	Morbidity 5-15\%; characterized by severe malnutrition, anasarca, refractory to treatment, high mortality.
	Fontan-Associated Liver Disease (FALDi)	Progressive hepatic fibrosis leading to cirrhosis and increased risk of hepatocellular carcinoma ($\text{HCC}$) in adulthood.
	Ventricular Failure	Single ventricle failure leading to low cardiac output and transplantation candidacy.
Long-term	Chronic kidney disease, neurodevelopmental delays, chronic restrictive lung disease, reduced aerobic capacity.

Prognosis

Factors Affecting Outcome ($\text{SVP}$ Post-Fontan)

• Negative Predictors: PVR $> 2 \text{ Woods units}\cdot \text{m}^2$, $\text{VEDP} > 15 \text{ mmHg}$, significant $\text{AV}$ valve regurgitation, poor ventricular function ($\text{EF} < 40\%$), presence of $\text{PLE}$ or severe $\text{FALDi}$.
• Positive Predictors: Low PVR, normal $\text{AV}$ valve function, younger age at Fontan completion, $\text{ECC}$ technique.

Survival

• Expected Survival: Approximately $80-90\%$ at 10 years, $70-80\%$ at 20 years, and $50-60\%$ at 30 years post-Fontan.
• Mortality: Most late deaths are related to progressive ventricular dysfunction, $\text{PLE}$, severe $\text{IART}$, or sudden cardiac death.

Quality of Life

Patients generally achieve functional Class I/II (NYHA) status for the first decade, but QoL often declines over time due to chronic fatigue, exercise limitation (peak $\text{VO}_2$ typically $60-70\%$ of predicted), and management of complications. Educational and vocational attainment is generally good, though psychological support is often required.

Prevention

• Primary (Pre-Fontan Optimization): Aggressive management of PVR (e.g., Sildenafil), maintaining normal ventricular function, and repairing $\text{AV}$ valve regurgitation before Fontan completion.
• Secondary (Early Detection): Strict adherence to annual surveillance protocols (CMR, Echo, $\text{NT}$-pro$\text{BNP}$, liver screening). Early recognition and treatment of $\text{IART}$ and fluid overload.
• Tertiary (Complication Management): Prophylactic anticoagulation to prevent thromboembolism. Prompt initiation of high-protein, $\text{MCT}$ diet and targeted medical therapy (e.g., steroids, heparin) upon diagnosis of $\text{PLE}$.

Special Populations

Pediatric

The Fontan circulation is generally well-tolerated in childhood. Key focus is on adequate growth, nutrition, and early detection of ventricular strain or pulmonary congestion to optimize time until Fontan completion.

Geriatric (Adult Congenital Heart Disease $\text{ACHD}$ Population)

As the population ages, focus shifts to managing cumulative chronic complications: * Increased prevalence of $\text{FALDi}$ and $\text{HCC}$. * Management of intractable atrial tachyarrhythmias (ablation often more challenging). * High threshold for considering heart transplantation or mechanical support.

Pregnancy

Pregnancy in Fontan patients is high-risk ($\text{WHO}$ Class III or IV). Increased volume load and hormonal changes significantly increase the risk of heart failure, arrhythmia, and thrombosis. * Management: Requires detailed counseling, close monitoring by a multidisciplinary $\text{ACHD}/\text{OB}$ team, often requiring prophylactic anticoagulation (e.g., $\text{LMWH}$) throughout pregnancy.

Comorbidities

• Obesity: Extremely detrimental, increasing PVR and systemic pressures; necessitates rigorous weight management.
• Systemic Hypertension: Must be aggressively treated to minimize afterload on the systemic ventricle. $\text{ACEi}$ or $\text{ARBs}$ are first-line.

Clinical Pearls

Diagnostic

• The mean Fontan pressure ($\text{P}_{\text{FO}}$) measured by catheterization is the single most predictive hemodynamic variable of long-term outcome. Goal is $< 15 \text{ mmHg}$.
• If a Fontan patient presents with $\text{SpO}2 < 85\%$ without clear pulmonary disease, suspect a failing Fontan (high $\text{P}{\text{FO}}$ driving collateral flow) or significant left-sided $\text{AV}$ valve regurgitation.
• Do not dismiss chronic diarrhea or minor edema: These may be the earliest signs of Protein-Losing Enteropathy, which significantly worsens prognosis.

Treatment

• Optimize PVR: $\text{PVR}$ optimization (Sildenafil, Prostacyclins) must precede any major surgical revision or consideration for transplantation.
• Anticoagulation: Warfarin is mandatory for patients with $\text{IART}$, history of $\text{PA}$ thrombus, or those with significant ventricular dysfunction ($\text{EF} < 45\%$).
• Fluid Management: Fluid restriction and diuretics are central, but avoid hypovolemia, as it can precipitate low cardiac output. Titrate carefully against symptoms and $\text{JVP}$.

Pitfalls

• Attributing all shortness of breath to a simple cold or deconditioning: Aggressively investigate for early signs of $\text{AV}$ valve regurgitation or Fontan circuit obstruction.
• Ignoring Liver Disease: $\text{FALDi}$ is universal. Failure to screen regularly for fibrosis and $\text{HCC}$ can lead to missed opportunities for early intervention or surveillance intensification.
• Over-reliance on $\text{EF}$: The single ventricle $\text{EF}$ (often based on geometric assumptions in Echo) can be misleading. CMR volumes and strain metrics provide superior functional assessment.

Recent Updates

Guidelines

• 2019 $\text{AHA}$/$\text{ACC}$ Guidelines for $\text{ACHD}$: Strongly recommend comprehensive multidisciplinary care (ACHD Center) and standardized long-term surveillance protocols, particularly emphasizing $\text{CMR}$ and $\text{FALDi}$ screening.
• Anticoagulation: Current guidelines favor indefinite anticoagulation with Vitamin K antagonists (Warfarin) over Aspirin monotherapy, particularly in $\text{ECC}$ Fontan patients, given the high thromboembolic risk.

Evidence

• $\text{FALDi}$ Screening: Growing consensus emphasizes annual or biennial abdominal imaging (Ultrasound/CMR) and serum markers (e.g., $\text{AFP}, \text{APRI}$ score) to screen for progression to cirrhosis and $\text{HCC}$ starting in late adolescence or early adulthood.
• Ventricular Support: While $\text{VADs}$ were historically challenging, newer transapical and durable $\text{VADs}$ are increasingly being used as bridges to transplantation in selected patients with failing systemic ventricles.

Controversies

• Routine $\text{PVR}$/Fenestration: Debate continues regarding the need for routine cardiac catheterization every 5 years versus risk-based indication, and whether routine late fenestration closure is beneficial or detrimental.
• Optimal Anticoagulation: The role of direct oral anticoagulants ($\text{DOAC}$s) is still being studied; they are not yet standard of care due to limited data in the complex hemodynamics and high thrombus burden of the Fontan circuit.

Key References

• Silversides et al. The Fontan Circulation: Challenges and Future Directions. Journal of the American College of Cardiology (2020).
• $\text{AHA}/\text{ACC}$ Guideline for the Management of Adults with Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines (2019).
• Ginde and Yetman. Protein-losing enteropathy after Fontan operation. Current Opinion in Cardiology (2018).
• Valente et al. Cardiovascular Magnetic Resonance in Single Ventricle and Fontan Palliation. Circulation (2018).